RT Journal Article
SR Electronic
T1 Goat PRP14 (gPRP14) has xeno-antigenic properties and works as a vaccine in preclinical models of cancer
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2022.07.04.498594
DO 10.1101/2022.07.04.498594
A1 Saverio Minucci
A1 Benedetta Bussolati
A1 Paul E. Massa
A1 Alessia Brossa
A1 Roberto Ravasio
A1 Mona Saadeldin
A1 Genny Degani
A1 Elli Papadimitriou
A1 Amal Saadeldin
A1 Antonio Salvaggio
A1 Cristina Visintin
A1 Giulia Rizzi
A1 Stefano Ricagno
A1 Laura Popolo
A1 Maria Antonietta Vanoni
A1 Pier Giuseppe Pelicci
YR 2022
UL http://biorxiv.org/content/early/2022/07/04/2022.07.04.498594.abstract
AB We studied the activity of recombinant goat PRP14 (gPRP14), a member of the RID protein family, as a xeno-antigen in preclinical models of cancer. Antisera from rabbits and mice immunized with gPRP14 showed strong reactivity against several tumor cell types, which was absent towards normal cells: the tumor selectivity was related to surface and intra-cellular expression in tumor cells, and to an exclusively intra-cellular localization in normal cells. In vitro, binding to tumor cells was followed by cytotoxicity which could be rescued by the addition of excess soluble antigen. In vivo, an anti-tumor activity of immunization with gPRP14 was observed in murine syngeneic models of breast cancer and melanoma: the anti-tumor response was present when gPRP14 was administered in a preventive setting, and persisted upon repeated challenges with tumor cells in long-term survivor mice. Finally, we showed that both the humoral and T-cell mediated responses are needed for the optimal anti-tumor effect in the murine melanoma model. Thus, we have performed an initial characterization of gPRP14 as a cancer vaccine, which -given the potential wide range of tumor cells positive for the antigen-appears as a promising, novel immunotherapy.Competing Interest StatementThe authors have declared no competing interest.